Skip to main content
. 2011 Aug 26;120(1):105–111. doi: 10.1289/ehp.1103573

Table 3.

IRRs for NHL and 95% CI in association with adipose tissue concentrations of PCBs.

Compound/concentrationa (μg/kg lipids) n (cases/subcohort) IRR (95% CI)
Model 1b Model 2c
PCB-118
10–25 53/50 1.00 1.00
25–34 63/62 0.97 (0.57, 1.66) 0.88 (0.50, 1.56)
34–48 58/56 1.00 (0.59, 1.71) 0.96 (0.55, 1.65)
48–62 34/38 0.78 (0.42, 1.45) 0.67 (0.34, 1.31)
62–150 25/27 0.79 (0.40, 1.55) 0.72 (0.36, 1.44)
Linear estimate per IQRd 233/233 0.92 (0.72, 1.17) 0.88 (0.68, 1.14)
PCB-156
13–28 62/53 1.00 1.00
28–34 51/63 0.56 (0.33, 0.96) 0.59 (0.34, 1.02)
34–41 54/59 0.64 (0.38, 1.09) 0.68 (0.40, 1.16)
41–50 45/35 0.83 (0.46, 1.50) 0.94 (0.51, 1.75)
50–88 23/26 0.57 (0.28, 1.15) 0.66 (0.31, 1.37)
Linear estimate per IQRd 235/236 0.95 (0.75, 1.20) 1.01 (0.79, 1.29)
PCB-99
9–20 32/49 1.00 1.00
20–27 42/41 1.63 (0.88, 3.02) 1.60 (0.85, 3.01)
27–37 53/44 1.59 (0.87, 2.91) 1.56 (0.84, 2.89)
37–47 24/27 1.20 (0.58, 2.48) 1.20 (0.58, 2.49)
47–110 20/16 1.45 (0.61, 3.43) 1.42 (0.59, 3.40)
Linear estimate per IQRd 171/177 1.10 (0.83, 1.44) 1.09 (0.83, 1.43)
PCB-138
29–100 53/49 1.00 1.00
100–140 44/69 0.66 (0.38, 1.13) 0.66 (0.38, 1.14)
140–180 74/63 1.05 (0.63, 1.75) 1.04 (0.62, 1.74)
180–230 41/34 1.25 (0.67, 2.31) 1.25 (0.67, 2.33)
230–380 26/28 0.68 (0.34, 1.34) 0.68 (0.34, 1.36)
Linear estimate per IQRd 238/243 0.99 (0.78, 1.25) 0.99 (0.78, 1.26)
PCB-153
98–240 56/55 1.00 1.00
240–300 57/61 0.87 (0.52, 1.47) 0.88 (0.52, 1.50)
300–370 56/73 0.64 (0.38, 1.07) 0.67 (0.40, 1.12)
370–430 42/28 1.38 (0.75, 2.53) 1.50 (0.81, 2.78)
430–730 28/27 0.79 (0.39, 1.57) 0.85 (0.42, 1.73)
Linear estimate per IQRd 239/244 0.94 (0.75, 1.19) 0.97 (0.77, 1.23)
PCB-170
37–87 57/61 1.00 1.00
87–100 47/41 1.09 (0.63, 1.89) 1.19 (0.68, 2.09)
100–130 69/78 0.79 (0.48, 1.30) 0.93 (0.54, 1.59)
130–150 42/32 1.16 (0.64, 2.08) 1.46 (0.75, 2.83)
150–230 23/31 0.64 (0.32, 1.29) 0.80 (0.38, 1.69)
Linear estimate per IQRd 238/243 0.89 (0.68, 1.18) 0.98 (0.72, 1.33)
Compound/concentrationa (μg/kg lipids) n (cases/subcohort) IRR (95% CI)
Model 1b Model 2c
PCB-180
71–170 53/60 1.00 1.00
170–200 55/52 0.94 (0.56, 1.67) 1.03 (0.60, 1.77)
200–240 61/54 1.04 (0.62, 1.83) 1.19 (0.69, 2.05)
240–290 49/48 0.98 (0.50, 1.59) 1.09 (0.59, 2.01)
290–480 21/31 0.54 (0.27, 1.08) 0.69 (0.32, 1.46)
Linear estimate per IQRd 239/245 0.90 (0.75, 1.08) 0.99 (0.77, 1.27)
PCB-183
6–19 59/53 1.00 1.00
19–24 35/54 0.59 (0.34, 1.05) 0.58 (0.32, 1.03)
24–31 69/60 0.92 (0.55, 1.53) 0.91 (0.54, 1.51)
31–39 40/34 1.03 (0.56, 1.90) 1.03 (0.56, 1.90)
39–65 23/26 0.66 (0.33, 1.31) 0.68 (0.34, 1.37)
Linear estimate per IQRd 226/227 0.87 (0.70, 1.08) 0.88 (0.70, 1.10)
PCB-187
17–46 61/58 1.00 1.00
46–56 49/62 0.68 (0.40, 1.15) 0.69 (0.40, 1.17)
56–68 62/60 0.90 (0.54, 1.51) 0.97 (0.57, 1.64)
68–84 44/33 1.12 (0.60, 2.07) 1.30 (0.68, 2.47)
84–140 22/27 0.62 (0.30, 1.27) 0.69 (0.33, 1.44)
Linear estimate per IQRd 238/240 0.88 (0.71, 1.11) 0.92 (0.73, 1.15)
PCB-201
6–15 43/47 1.00 1.00
15–19 62/61 0.91 (0.52, 1.59) 0.98 (0.56, 1.73)
19–23 58/47 1.10 (0.62, 1.97) 1.20 (0.66, 2.21)
23–28 36/44 0.69 (0.37, 1.29) 0.82 (0.41, 1.67)
28–45 25/28 0.73 (0.34, 1.56) 0.88 (0.38, 2.03)
Linear estimate per IQRd 224/227 0.85 (0.64, 1.13) 0.93 (0.68, 1.28)
ΣPCBe
150–770 62/59 1.00 1.00
770–939 55/66 0.74 (0.45, 1.24) 0.74 (0.44, 1.24)
939–1,143 57/62 0.78 (0.47, 1.30) 0.81 (0.48, 1.35)
1,143–1,351 42/32 1.08 (0.59, 1.95) 1.15 (0.63, 2.11)
1,351–2,157 23/26 0.65 (0.32, 1.33) 0.71 (0.34, 1.45)
Linear estimate per IQRf 239/245 0.95 (0.76, 1.19) 0.99 (0.79, 1.25)
ΣPCBimmuneg
150–530 60/58 1.00 1.00
530–650 55/63 0.77 (0.46, 1.30) 0.79 (0.47, 1.34)
650–790 59/65 0.77 (0.47, 1.29) 0.82 (0.49, 1.38)
790–930 42/32 1.15 (0.64, 2.09) 1.29 (0.70, 2.38)
930–1,490 23/27 0.62 (0.31, 1.26) 0.68 (0.33, 1.41)
Linear estimate per IQRh 239/245 0.95 (0.76, 1.18) 0.99 (0.78, 1.24)